This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Medtronic (MDT) Tops Q2 Earnings on Strong Segmental Growth
by Zacks Equity Research
Medtronic (MDT) demonstrated improved performances at CER on growth in all business segments. However, costs continue to escalate.
Medtronic Moves a Step Ahead With Mazor Robotics Buyout
by Zacks Equity Research
Medtronic's (MDT) resolve to take over the Israel-based robotic surgical guidance systems company, Mazor Robotics, adheres to its goal to grow in the sphere of robotics spine surgery.
Medtronic (MDT) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Medtronic (MDT) delivered earnings and revenue surprises of 7.02% and 1.77%, respectively, for the quarter ended October 2018. Do the numbers hold clues to what lies ahead for the stock?
Will Diabetes Arm Aid Medtronic's (MDT) Q2 Earnings Again?
by Zacks Equity Research
Medtronic (MDT) gains traction from the U.S. launch of its Guardian Connect product. This enables the company to further capture a considerable share in the $1-billion standalone CGM market.
Will Strong RTG Arm Shape Medtronic's (MDT) Q2 Earnings?
by Zacks Equity Research
Medtronic (MDT) poised to gain on continued RTG business growth in Q2.
Here's What Will Shape Medtronic's (MDT) Fate in Q2 Earnings
by Zacks Equity Research
Medtronic (MDT) is expected to maintain a decent market share in the core pacing banking, backed by the continued rollout of Micra Transcatheter Pacing System.
Is Medtronic (MDT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (MDT) Outperforming Other Medical Stocks This Year?
Medtronic (MDT) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Medtronic (MDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bear of the Day: NuVasive (NUVA)
by Kevin Cook
Another earnings hiccup puts this spinal surgery innovator back in the cellar of the Zacks Rank
Medtronic (MDT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Medtronic (MDT) closed at $91.55 in the latest trading session, marking a +1.93% move from the prior day.
United Therapeutics (UTHR) Q3 Earnings Beat but Stock Dips
by Zacks Equity Research
United Therapeutics (UTHR) beats estimates for both earnings and sales in the third quarter but shares sink 10%.
IntriCon (IIN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
IntriCon's (IIN) robust medical and hearing health businesses are likely to drive its third-quarter 2018 results.
Has Medtronic (MDT) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (MDT) Outperforming Other Medical Stocks This Year?
Will Medtronic (MDT) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Medtronic (MDT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
DexCom Launches CLARITY Mobile App, Strengthens CGM Profile
by Zacks Equity Research
DexCom (DXCM) benefits from the diabetes care space as it adopts cloud-based services for Continuous Glucose Monitoring.
IBM Beats on Q2 Earnings, Stock Down on Top-Line Decline
by Zacks Equity Research
IBM's third-quarter 2018 earnings benefit from higher pre-tax margin expansion and a lower share count.
The Zacks Analyst Blog Highlights: Masimo, Medtronic, Garmin and DexCom
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Masimo, Medtronic, Garmin and DexCom
Wearable Medical Device Boom Puts These 3 Stocks in Focus
by Nabaparna Bhattacharya
Americans depend on wearable medical devices for fitness tracking, blood pressure maintenance, self-glucose monitoring and more. Here, we discuss major companies that are raking in huge profits.
US Diabetes Market Gaining Momentum: 3 Stocks in Focus
by Sreyoshi Mukherjee
A rising geriatric population and lifestyle disorders are expanding the U.S. diabetic population.
Baxter (BAX) Collaborates With USC CBC to Digitize Healthcare
by Zacks Equity Research
Baxter's (BAX) efforts to digitize healthcare solutions are likely to fortify its foothold in the highly competitive MedTech industry.
Bull of the Day: Penumbra (PEN)
by Kevin Cook
Innovation in stroke treatment with catheter-based technologies has launched a new rocket of med-tech
Top Stock Reports for Boeing, NVIDIA & Medtronic
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Boeing (BA), NVIDIA (NVDA) and Medtronic (MDT).
Medtronic to Buy Mazor Robotics for Robotic Spine Surgery
by Zacks Equity Research
The consolidation will combine Medtronic's (MDT) spine implants, navigation and intra-operative imaging technology with Mazor Robotics' robotic-assisted surgery (RAS) systems.
3 MedTech Stocks for Safe Returns as Hurricane Fears Peak
by Sweta Jaiswal
With the hurricane season at the peak, we bring three safe picks for investors.
Medtronic (MDT) Up 0.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.